Abbott Laboratories (ABT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2016 | 12-2015 | 09-2015 | 06-2015 | 03-2015 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 316,000 | 4,423,000 | 3,656,000 | 3,076,000 | 2,292,000 |
| Depreciation Amortization | 347,000 | 1,472,000 | 1,106,000 | 723,000 | 371,000 |
| Accounts receivable | -4,000 | -171,000 | -151,000 | -125,000 | -90,000 |
| Other Working Capital | -99,000 | -156,000 | -364,000 | -335,000 | -218,000 |
| Other Operating Activity | -653,000 | -2,602,000 | -2,109,000 | -2,396,000 | -2,353,000 |
| Operating Cash Flow | $-93,000 | $2,966,000 | $2,138,000 | $943,000 | $2,000 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | N/A | N/A | -2,626,000 | N/A | N/A |
| PPE Investments | -243,000 | -1,110,000 | -862,000 | -451,000 | -235,000 |
| Net Acquisitions | 25,000 | 2,285,000 | 2,285,000 | 2,516,000 | 230,000 |
| Purchase Of Investment | N/A | -4,933,000 | N/A | -2,056,000 | N/A |
| Sale Of Investment | 446,000 | 4,112,000 | N/A | N/A | -213,000 |
| Other Investing Activity | -2,000 | 52,000 | 43,000 | 28,000 | 13,000 |
| Investing Cash Flow | $226,000 | $406,000 | $-1,160,000 | $37,000 | $-205,000 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | -1,281,000 | -2,019,000 | N/A | N/A |
| Debt Issued | N/A | 2,485,000 | 2,485,000 | 2,485,000 | 2,485,000 |
| Debt Repayment | -7,000 | -57,000 | -36,000 | -33,000 | -10,000 |
| Common Stock Issued | 87,000 | 314,000 | 263,000 | 213,000 | 156,000 |
| Common Stock Repurchased | -519,000 | -2,237,000 | -1,349,000 | -1,347,000 | -1,346,000 |
| Dividend Paid | -385,000 | -1,443,000 | -1,083,000 | -724,000 | -364,000 |
| Other Financing Activity | -608,000 | -17,000 | 0 | -1,518,000 | -1,471,000 |
| Financing Cash Flow | $-1,432,000 | $-2,236,000 | $-1,739,000 | $-924,000 | $-550,000 |
| Exchange Rate Effect | -368,000 | -198,000 | -170,000 | -71,000 | -84,000 |
| Beginning Cash Position | 5,001,000 | 4,063,000 | 4,063,000 | 4,063,000 | 4,063,000 |
| End Cash Position | 3,334,000 | 5,001,000 | 3,132,000 | 4,048,000 | 3,226,000 |
| Net Cash Flow | $-1,667,000 | $938,000 | $-931,000 | $-15,000 | $-837,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | -93,000 | 2,966,000 | 2,138,000 | 943,000 | 2,000 |
| Capital Expenditure | -243,000 | -1,110,000 | -862,000 | -451,000 | -235,000 |
| Free Cash Flow | -336,000 | 1,856,000 | 1,276,000 | 492,000 | -233,000 |